Vascular reactivity in heart failure: Role of myosin light chain phosphatase

Circulation Research

Volumn 95, Issue 6, 2004, Pages 612-618

  Karim, Syed M ^b   Rhee, Albert Y ^a   Given, Allison M ^a   Faulx, Michael D ^b   Hoit, Brian D ^b   Brozovich, Frank V ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cGMP; Congestive heart failure; Nitric oxide; Vascular function

Indexed keywords

8 BROMO CYCLIC GMP; ISOENZYME; LEUCINE ZIPPER PROTEIN; MYOSIN LIGHT CHAIN KINASE; MYOSIN LIGHT CHAIN PHOSPHATASE; NITRIC OXIDE;

ALTERNATIVE RNA SPLICING; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BIOMECHANICS; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOSE RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SUBUNIT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; ILIAC ARTERY; LEFT CORONARY ARTERY; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ALTERNATIVE SPLICING; ANIMALS; BLOTTING, WESTERN; CALCIUM; CARRIER PROTEINS; CORONARY VESSELS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; LIGATION; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; NITRIC OXIDE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASODILATION;

EID: 4644285523     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000142736.39359.58     Document Type: Article

References (43)

1. Francis GS, Cohn JN. Heart Failure: Mechanisms of cardiac and vascular dysfunction and the rationale for pharmacolgic intervention. FASEB J. 1990;4:3068-3075.
2. Negrao CE, Hamilton MA, Fonarow GC, Hage A, Moriguchi JD, Middlekauff HR. Impaired endothelium-mediated vasodilation is not the principal cause of vasoconstriction in heart failure. Am J Physiol. 2000; 278:H168-H174.
3. Nakamura M, Arakawa N, Yoshida H, Saitoh S, Kon H, Hiramori K. Blunted peripheral vasodilatory response is a hallmark of progressive deterioration in mild to moderate congestive heart failure. J Card Fail. 2001;7:38-44.
4. Abassi ZA, Gurbanov K, Mulroney SE, Potlog C, Opgenorth TJ, Hoffman A, Haramati A, Winaver J. Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: Role of angiotensin II. Circulation. 1997;96:3655-3664.
5. Thorin E, Lucas M, Cernacek P, Dupuis J. Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure. Am J Physiol. 2000;279:H844-H851.
6. Hirooka Y, Imaizumi T, Tagawa T, Shiramoto M, Endo T, Ando S, Takeshita A. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation. 1994;90:658-668.
7. Katz, SD, Biasucci L, Sabba C, Strom JA, Jondeau G, Galvao M, Solomon S, Nikolic SD, Forman R, LeJemtel TH. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19:918-925.
8. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
9. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong ML, et al. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
10. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490-498.
11. Hartshorne DJ. Biochemistry of the contractile process in smooth muscle. In: Johnson LR, ed, Physiology of the Gastrointestinal Tract. New York, NY: Raven Press; 1987:432-482.
12. Gong MC, Cohen P, Kitazawa T, Ikebe M, Masuo M, Somlyo AP, Somlyo AV. Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J Biol Chem. 1992;267:14662-14668.
13. Kamm KE, Stull JT. Regulation of smooth muscle contractile elements by second messengers. Ann Rev Physiol. 1989;51:299-313.
14. Gallagher PJ, Herring BP, Griffin SA, Stull JT. Molecular characterization of a mammalian smooth muscle myosin light chain kinase. J Biol Chem. 1991;266:23936-23944.
15. 2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-1358.
16. Lincoln TM. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther. 1989;41:479-502.
17. Hartshorne DJ, Ito M, Erdîdi F. Myosin light chain phosphatase: subunit composition, interactions and regulation. J Mus Research Cell Motil. 1998;19:325-341.
18. Dirksen WP, Vladic F, Fisher SA. A myosin phosphatase targeting subunit isoform transition defines a smooth muscle developmental phenotypic switch. Am J Physiol. 2000;278:C589-C600.
19. Khatri JJ, Joyce KM, Brozovich FV, Fisher SA. Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem. 2001;276:37250-37257.
20. Ogut O, Brozovich FV. Determinants of the contractile properties in the embryonic chicken gizzard and aorta. Am J Physiol. 2000;279:C1722-C1732.
21. Richards CT, Ogut O, Brozovich FV. Agonist-induced force enhancement. The role of isoforms and phosphorylation of the mysoin-targeting subunit of mysoin light chain phosphatase. J Biol Chem. 2002; 277:4422-4427.
22. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep. 1999;19:235-251.
23. Alioua A, Tanaka Y, Wallner M, Hofmann F, Ruth P, Meera P, Toro L. The large conductance, voltage-dependent, and calcium-sensitive K+ channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo. J Biol Chem. 1998;273:32950-32956.
24. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action. Biochim Biophys Acta. 1993;1178:153-175.
25. Fukao M, Mason HS, Britton FC, Kenyon JL, Horowitz B, Keef KD. Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem. 1999;274:10927-10935.
26. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Ia. Science. 1999;286:1583-1587.
27. Huang QQ, Fisher SA, Brozovich FV. Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation. J Biol Chem. 2004; 279:597-603.
28. Geenen DL, Malhotra A, Scheuer J. Regional variation in rat cardiac myosin isoenzymes and ATPase activity after infarction. Am J Physiol. 1989;256:H745-H750.
29. Geenen DL, Malhotra A, Liang D, Scheuer J. Ventricular function and contractile proteins in the infarcted overloaded rat heart. Cardiovasc Res. 1991;25:330-336.
30. Delp MD, Duan C, Mattson JP, Musch TI. Changes in skeletal muscle biochemistry and histology relative to fiber type in rats with heart failure. J Appl Physiol. 1997;83:1291-1299.
31. Symons JD, Stebbins CL, Musch TI. Interactions between angiotensin II and nitric oxide during exercise in normal and heart failure rats. J Appl Physiol. 1999;87:574-581.
32. Hoit BD, Castro C, Bultron G, Knight S, Matlib MA. Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail. 1999;5:324-333.
33. Rhee AY, Brozovich FV. The smooth muscle cross-bridge cycle studied using sinusoidal length perturbations. Biophys J. 2000;79:1511-1523.
34. Karagiannis P, Babu GJ, Periasamy M, Brozovich FV. The smooth muscle myosin seven amino acid heavy chain insert's kinetic role in the crossbridge cycle for mouse bladder. J Physiol. 2003;547:463-473.
35. Fisher SA, Ikebe M, Brozovich F. Endothelin-1 alters the contractile phenotype of cultured embryonic smooth muscle cells. Circ Res. 1997; 80:885-893.
36. Huang QQ, Fisher SA, Brozovich FV. Forced expression of essential myosin light chain isoforms demonstrates their role in smooth muscle force production. J Biol Chem. 1999;274:35095-35098.
37. Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: From the regulation of tone to gene expression. J Appl Physiol. 2001;91:1421-1430.
38. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
39. Nagao T, Illiano S, Vanhoutte PM. Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-L-arginine in rats. Am J Physiol. 1992;263:H1090-H1094.
40. Pfitzer G, Merkel L, Ruegg JC, Hofmann F. Cyclic GMP-dependent protein kinase relaxes skinned fibers from guinea pig taenia coli but not from chicken gizzard. Pflugers Arch. 1986;407:87-91.
41. Surks HK, Mendelsohn ME. Dimerization of cGMP-dependent protein kinase 1α and the myosin-binding subunit of myosin phosphatase: role of leucine zipper domains. Cell Signal. 2003;15:937-944.
42. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Research. 1979;44:503-512.
43. Langsetmo K, Stafford WF III, Mabuchi K, Tao T. Recombinant small subunit of smooth muscle myosin light chain phosphatase. Molecular properties and interactions with the targeting subunit. J Biol Chem. 2001;276:34318-34322.